Drug Trial Radar · NCT07934927
A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal Melanoma
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Sep 29, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-arm, open-label Phase II clinical study. The main purpose of this study is to evaluate the effectiveness of nab-paclitaxel combined with retlirafusp alfa injection and apatinib mesylate in patients with advanced mucosal melanoma. Participants will receive treatment with nab-paclitaxel combined with retlirafusp alfa injection and apatinib mesylate. Each treatment cycle lasts 3 weeks, and participants will receive a total of 6 cycles. Participants whose disease does not progress after the initial treatment will continue maintenance therapy with apatinib mesylate combined with retlirafusp alfa injection until their disease progresses or they experience intolerable side effects. After enrollment, participants will undergo safety visits before each dose on Day 1 and Day 21 of each treatment cycle. Tumor imaging assessments will be performed before treatment and after every 2 to 4 cycles of treatment. Clinical response will be evaluated by radiologists according to the RECIST 1.1 criteria. Researchers will monitor participants for any adverse events throughout the study and will grade the severity of these events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. After treatment is completed, participants will be followed for 12 weeks for safety monitoring, and long-term survival follow-up will continue.
Conditions
- Melanoma
- Immune Checkpoint Inhibitor
Interventions
Retlirafusp Alfa InjectionDrug
Drug: Nab-paclitaxel Injection Nab-paclitaxel 200 mg/m² IV infusion Q3W Drug: Retlirafusp Alfa Injection Retlirafusp Alfa diluted in 250 mL normal saline IV, administered 30 minutes before chemotherapy, Q3W Drug: Apatinib Mesylate Tablet Apatinib Mesylate 250 mg PO QD Regimen: Nab-paclitaxel + Retlirafusp Alfa + Apatinib Mesylate, Q3W × 6 cycles (combination phase); maintenance: Apatinib Mesylate + SHR-1701 until disease progression or unacceptable toxicit
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR: CR+PR)Time frame: up to 18 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun yat-sen uniersity
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.